These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 29776968)

  • 61. Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
    Hyde KM; Blonde GD; le Roux CW; Spector AC
    Physiol Behav; 2017 Aug; 177():4-12. PubMed ID: 28366815
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Delayed administration of the GLP-1 receptor agonist liraglutide improves metabolic and functional recovery after cerebral ischemia in rats.
    Dong W; Miao Y; Chen A; Cheng M; Ye X; Song F; Zheng G
    Neurosci Lett; 2017 Feb; 641():1-7. PubMed ID: 28122257
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials.
    Tonneijck L; Muskiet MHA; Smits MM; Bjornstad P; Kramer MHH; Diamant M; Hoorn EJ; Joles JA; van Raalte DH
    Diabetes Obes Metab; 2018 May; 20(5):1235-1245. PubMed ID: 29341461
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor.
    Douros JD; Lewis AG; Smith EP; Niu J; Capozzi M; Wittmann A; Campbell J; Tong J; Wagner C; Mahbod P; Seeley R; D'Alessio DA
    Diabetes; 2018 Aug; 67(8):1504-1511. PubMed ID: 29759973
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synergistic metabolic benefits of an exenatide analogue and cholecystokinin in diet-induced obese and leptin-deficient rodents.
    Trevaskis JL; Sun C; Athanacio J; D'Souza L; Samant M; Tatarkiewicz K; Griffin PS; Wittmer C; Wang Y; Teng CH; Forood B; Parkes DG; Roth JD
    Diabetes Obes Metab; 2015 Jan; 17(1):61-73. PubMed ID: 25204356
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms.
    Krieger JP
    Peptides; 2020 Sep; 131():170342. PubMed ID: 32522585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D; Hahn M; Correll CU; Fink-Jensen A; Russell AW; Bak N; Broberg BV; Larsen J; Ishøy PL; Vilsbøll T; Knop FK; Kisely S; Ebdrup BH
    Diabetes Obes Metab; 2019 Feb; 21(2):293-302. PubMed ID: 30187620
    [TBL] [Abstract][Full Text] [Related]  

  • 69. GLP-1 receptor stimulation of the lateral parabrachial nucleus reduces food intake: neuroanatomical, electrophysiological, and behavioral evidence.
    Richard JE; Farkas I; Anesten F; Anderberg RH; Dickson SL; Gribble FM; Reimann F; Jansson JO; Liposits Z; Skibicka KP
    Endocrinology; 2014 Nov; 155(11):4356-67. PubMed ID: 25116706
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway.
    Ke J; Liu Y; Yang J; Lu R; Tian Q; Hou W; Wang G; Wei R; Hong T
    Sci Rep; 2017 Feb; 7():41085. PubMed ID: 28145471
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial.
    Mashayekhi M; Beckman JA; Nian H; Garner EM; Mayfield D; Devin JK; Koethe JR; Brown JD; Cahill KN; Yu C; Silver H; Niswender K; Luther JM; Brown NJ
    Diabetes Obes Metab; 2023 Feb; 25(2):570-580. PubMed ID: 36306151
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterization of the Glucagonlike Peptide-1 Receptor in Male Mouse Brain Using a Novel Antibody and In Situ Hybridization.
    Jensen CB; Pyke C; Rasch MG; Dahl AB; Knudsen LB; Secher A
    Endocrinology; 2018 Feb; 159(2):665-675. PubMed ID: 29095968
    [TBL] [Abstract][Full Text] [Related]  

  • 73. GLP-1R agonists for the treatment of obesity: a patent review (2015-present).
    Liu C; Zou Y; Qian H
    Expert Opin Ther Pat; 2020 Oct; 30(10):781-794. PubMed ID: 32799587
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolism-mediated suppression of AMPK and is impaired by central fructose.
    Burmeister MA; Ayala J; Drucker DJ; Ayala JE
    Am J Physiol Endocrinol Metab; 2013 Apr; 304(7):E677-85. PubMed ID: 23341495
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Glucagon-like peptide-1 receptor action in the vasculature.
    Almutairi M; Al Batran R; Ussher JR
    Peptides; 2019 Jan; 111():26-32. PubMed ID: 30227157
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect.
    Sisley S; Gutierrez-Aguilar R; Scott M; D'Alessio DA; Sandoval DA; Seeley RJ
    J Clin Invest; 2014 Jun; 124(6):2456-63. PubMed ID: 24762441
    [TBL] [Abstract][Full Text] [Related]  

  • 78. L-arginine promotes gut hormone release and reduces food intake in rodents.
    Alamshah A; McGavigan AK; Spreckley E; Kinsey-Jones JS; Amin A; Tough IR; O'Hara HC; Moolla A; Banks K; France R; Hyberg G; Norton M; Cheong W; Lehmann A; Bloom SR; Cox HM; Murphy KG
    Diabetes Obes Metab; 2016 May; 18(5):508-18. PubMed ID: 26863991
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Liraglutide protects against lethal renal ischemia-reperfusion injury by inhibiting high-mobility group box 1 nuclear-cytoplasmic translocation and release.
    Li Y; Xu B; Yang J; Wang L; Tan X; Hu X; Sun L; Chen S; Zhu L; Chen X; Chen G
    Pharmacol Res; 2021 Nov; 173():105867. PubMed ID: 34481074
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
    Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
    Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.